Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment for extensive stage small cell lung cancer. The primary endpoint of the study was the 1-year overall survival rate.

Trial Details

NCT ID

NCT06739928

Phase

PHASE2

Sponsor

Guangzhou Institute of Respiratory Disease

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Irinotecan liposome (II) combined with adebrelimab and carboplatin
etoposide combined with adebrelimab and carboplatin

Locations (sample)

Guangzhou, Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

Pathologically confirmed small cell lung cancer (SCLC), staged as extensive-stage SCLC (ES-SCLC) according to the VALG staging system;
No prior systemic treatment received;
At least a 6-month interval between the last treatment (radiation therapy and chemotherapy) and diagnosis of extensive-stage SCLC;
Showing at least one target lesion (RECIST 1.1) that has not been previously irradiated;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →